Issue 19, 2018

A cancer specific oxaliplatin-releasing Pt(iv)-prodrug

Abstract

We prepared a Pt(IV)-prodrug, which under cancer specific conditions (elevated concentration of reactive oxygen species, ROS) releases a DNA-binding drug oxaliplatin as well as ROS-amplifying drugs p-quinone methide and N-alkylferrocenium. Due to the concerted action of these components, an excellent anticancer effect was achieved: IC50 = 0.4 ± 0.1 μM for human ovarian carcinoma A2780 cells. Importantly, the prodrug was found to be 45-fold less toxic to normal cells (HDFa).

Graphical abstract: A cancer specific oxaliplatin-releasing Pt(iv)-prodrug

Supplementary files

Article information

Article type
Communication
Submitted
13 Apr 2018
Accepted
23 Apr 2018
First published
23 Apr 2018

Dalton Trans., 2018,47, 6679-6682

A cancer specific oxaliplatin-releasing Pt(IV)-prodrug

V. Reshetnikov, A. Arkhypov, P. R. Julakanti and A. Mokhir, Dalton Trans., 2018, 47, 6679 DOI: 10.1039/C8DT01458B

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements